First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis: A Comprehensive Overview

By Johnston Jessica  

Drugs, Vol. 72, Iss. 9, 2012-06 ,pp. : 1195-1211

Adis International

Access to resources Recommend Favorite

Emerging therapies in multiple sclerosis

By Farrell Rachel   Heaney Dominic   Giovannoni Gavin  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 797-816

Informa Healthcare

Access to resources Recommend Favorite

Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis

By Bedlack Richard S   Traynor Bryan J   Cudkowicz Merit E  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 2, 2007-05 ,pp. : 229-252

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

By Gani Ray  

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 617-627

Adis International

Access to resources Recommend Favorite

Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

By Morren John A   Galvez-Jimenez Nestor  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 297-320

Informa Healthcare

Access to resources Recommend Favorite